Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

Abstract Background Anlotinib showed significant survival benefits in advanced non‐small cell lung cancer (NSCLC) patients as a third‐ or further‐line treatment in the ALTER0303 trial. We aimed to evaluate the efficacy of anlotinib in patients with different histologies. Methods The ALTER0303 trial...

Full description

Bibliographic Details
Main Authors: Ying Cheng, Baohui Han, Kai Li, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Jianxing He, Yuankai Shi, Weiqiang Chen, Xiuwen Wang, Yi Luo, Kejun Nan, Faguang Jin, Baolan Li, Jing Zhu
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Cancer Medicine
Subjects:
ACC
anlotinib
antiangiogenesis
SCC
third‐line
Online Access:https://doi.org/10.1002/cam4.2913

Internet

https://doi.org/10.1002/cam4.2913

Similar Items